In the past 20 years, there has been a great advancement in knowledge pertaining to compliance with amblyopia treatments. The occlusion dose monitor introduced quantitative monitoring methods in patching, which sparked our initial understanding of the dose-response relationship for patching amblyopia treatment. This review focuses on current compliance knowledge and the impact it has on patching and atropine amblyopia treatment.
Introduction
Unilateral amblyopia is a visual impairment that is secondary to an abnormal binocular visual experience (e.g., strabismus, anisometropia, form deprivation) during early childhood. Unfortunately, amblyopia cannot be corrected immediately with optical correction alone. Although providing accurate optical correction can treat about 25% of children with amblyopia (Cotter et al., 2012) , the dominant approach to amblyopia treatment includes strategies to enhance visual input from the amblyopic eye (relative to the fellow eye). This can only be achieved by interventions that degrade visual input to the fellow eye. Currently, mainstream treatments for unilateral amblyopia are occlusion via patching or atropine penalization of the stronger fellow eye. Both treatments effectively generate significant visual acuity improvement in children if the patient follows the treatment regimens as described below:
(a) Patching treatment regimen: depending on the child's age and the severity of amblyopia, 2-6 h of daily patching is usually prescribed for a few months up to several years. The benefits of these patching regimens have been established for both moderate and severe amblyopia Repka et al., 2008; Wallace et al., 2006) .
(b) Atropine penalization treatment regimen: Atropine penalization blurs the near vision of the fellow eye with an eye drop. Atropine is often prescribed with a dosage of 2 drops per week to daily (7 drops per week) treatment. Compared to patching, atropine is more manageable for parents and requires less effort from patients . However, in order to achieve the same level of vision improvement associated with 3 months of patching, 6 months of atropine treatment is required (Pediatric-EyeDisease-Investigator-Group, 2003) . Such a result indicates that atropine treatment requires compliance for a longer period.
Both patching and atropine treatments require combined efforts from both children and their parents. Stewart (2005) reported that the occlusion dose is the leading factor for predicting a successful outcome in amblyopic children in agreement with other studies (Awan, Proudlock, & Gottlob, 2005; Loudon et al., 2006; Stewart et al., 2005 Stewart et al., , 2007b Stewart et al., , 2013 . Thus, both patching and atropine penalization depend on compliance, i.e., the ratio of actual patching/atropine dosage to the prescribed patching/atropine dosage in a certain treatment duration. The following article will review the current compliance knowledge relating to these two major amblyopia treatments: patching and atropine penalization.
Compliance with amblyopia treatments is generally low
Compliance can be classified into subjective compliance and objective compliance. Usually with a calendar log, self-report, or occasionally an interview, subjective compliance has been widely estimated in both previous patching and atropine treatment studies Pediatric-Eye-DiseaseInvestigator-Group, 2002; Repka et al., 2008) . In contrast, objective compliance is usually estimated with a monitoring device. Objective compliance with patching treatments has been estimated in Europe while no such study has been reported for atropine treatment compliance.
Subjective compliance with patching
Using self-report calendar logs and clinical interviews, the Pediatric Eye Disease Investigator Group (PEDIG) often classifies subjective compliance with the prescribed treatment into four categories: ''excellent'' (76%-100%), ''good'' (51%-75%), ''fair'' (26%-50%) and ''poor'' (0-25%) (Pediatric-Eye-Disease-Investigator- Group, 2002) . Overall, in PEDIG clinical trials, 50-70% of subjective compliance with patching has been reported. (Table 1) In addition, there have been many other studies investigating subjective compliance (Al-Yahya et al., 2012; Al-Zuhaibi et al., 2009; Pang et al., 2012) . For instance, Al-Zuhaibi et al. estimated compliance with patching treatments using questionnaires and parent subjective reports; they reported that only 45% of patients had good compliance (Al-Zuhaibi et al., 2009) . In a study on myopic anisometropic amblyopia, 41% of patients had excellent compliance and 47% of patients had good compliance (Pang et al., 2012) . Note that patients in clinical trials and research studies may comply with the prescribed treatment better than the general population.
Objective compliance with patching
Objective compliance with patching can be measured with an electronic device, an occlusion dose monitor (ODM), which measures skin conductance with a wire (Fielder et al., 1994 (Fielder et al., , 1995 or temperature with thermistors Simonsz et al., 1999) at the border of the patch. ODM debuted in the early 1990s (Fielder et al., 1994 (Fielder et al., , 1995 and has continued to be improved, refined and miniaturized (Chopovska et al., 2005; Fronius et al., 2006) . ODM records and reports occluding activities up to the precise minute, and therefore provides the factual daily occlusion dose (dose rate) and cumulative dose.
With ODM use, objective compliance is often defined as the percentage of hours of actual patching compared to the hours of prescribed patching (Stewart et al., 2007b; Tjiam et al., 2012 Tjiam et al., , 2013 . To understand compliance comprehensively, Wallace, Stewart et al. (2013) drew a distinction between the days in which no patching is undertaken (no-patch days) and the days in which at least some patching is undertaken (patch days). Three operational measures of compliance were considered: (1) Compliance: the percentage of actual patching hours to the total prescribed patching hours; (2) Patch day compliance: ignoring no-patch days (days on which no patching was undertaken), the percentage of actual patching hours to the total prescribed dosage in the patching days; (3) Patch day proportion: the percentage of actual patching days to the total prescribed patching days.
According to ODM studies, objective compliance with patching is as low as 44% (Awan, Proudlock, & Gottlob, 2005; Pradeep et al., 2014; Tjiam et al., 2013; Wallace, Stewart et al., 2013) to 57% . (Table 2 ) In addition, objective compliance variation among children was considerable, varying from 0 to 100% (Stewart et al., 2004) .
Compliance is dynamic
Compliance variation within a child over time can be considerable Stewart et al., 2004) . In addition to generally low compliance with patching, compliance follows a dynamic pattern, as it usually decreases over time. Not surprisingly, in 3-to 8-year-old children, compliance is lower when longer treatments are required Wallace, Stewart et al., 2013) . In Fig. 1 , the mean compliance decreased from 60% at the beginning to 40% by the 50th day, and to 30% by the 100th day . Similar significant decreasing patterns of compliance over time were found in older children (7-16 years old) too (Fronius, Bachert, & Luchtenberg, 2009 ). Interestingly, Loudon et al. reported that the dynamics of compliance might differ with intervention; compliance in their educational cartoon story intervention group decreased less than the reference group after 1 week of the study . Compliance also varies by days of the week. For instance, weekends were not good compliance days, compared with weekdays .
In order to improve compliance, we must not only increase the average compliance, but we must also maintain a higher compliance level and/or reverse the decreasing trend of compliance over time.
Comparison of subjective and objective compliance with patching
Studies with ODM offer us a chance to compare objective compliance with subjective compliance. For example, diaries detailing patch time were inaccurate, and parents patched more to compensate after missing one or two days (''treatment days'') (Simonsz et al., 1999) . Subjective compliance is often better matched to the prescribed regimen than to the objective data, with instances of both under and over occlusion (Fielder et al., 1995) . These findings emphasize the shortcomings of subjective compliance reporting.
Subjective compliance with atropine penalization
Generally, atropine penalization was assumed to have a higher rate of compliance for the following reasons: (1) It is easy to manage for parents and less disruptive to the child's daily life than traditional patching. (2) It is associated with lower psychosocial or cosmetic issues. (3) Since the cycloplegic effect of topical atropine usually lasts for several days, imperfect compliance with atropine may not impact the treatment as much as imperfect compliance with patching. Therefore, atropine treatment appears to be more favorable to the child and family (Felius et al., 2010; . However, atropine penalization has some disadvantages that may affect patient compliance. As a pharmaceutical, atropine may have more serious adverse effects than the adhesive patch. Instead of irritating the skin and generating heat/sweat, as sometimes seen in patching treatments, atropine could induce visionrelated side effects, including light sensitivity, conjunctival irritation, eye pain, and degraded pursuit tracking performance (Penetar & Beatrice, 1986) . Atropine could also induce systemic side effects such as headaches and tachycardia (Penetar, Haegerstrom-Portnoy, & Jones, 1988) . Sometimes the side effects can be more serious in specific patient populations, such as children with Down Syndrome (Smith, 1994) .
For atropine penalization, subjective compliance has been estimated and reported in a few PEDIG studies (Table 3) . Subjective compliance with atropine penalization treatment varies from 59% to 94%. It is generally higher than subjective compliance with patching treatment, but like patching, shows considerable between-patient variability. Moreover, subjective compliance with atropine treatment is lower, on average, in older children (Scheiman et al., 2008) than in younger amblyopes (PediatricEye-Disease-Investigator-Group, 2002 (Table 3) .
To estimate atropine compliance objectively, Tejedor et al. used dynamic retinoscopy to test the patient's ability to accommodate; they reported 12.9% non-compliance (Tejedor & Ogallar, 2008) . Because such an objective method did not track the whole process, it may have under-or over-estimated objective compliance. Objective compliance with atropine treatment was also mentioned as being assessed by checking pupil fixation, but there were no further detailed reports (Foley-Nolan, McCann, & O'Keefe, 1997).
Compliance and the dose-response relationship
Although we generally believe that low compliance will result in poor vision improvement (which assumes that the recommended patching/atropine dosage is, in fact, the most effective), . objective evidence to support this hypothesis was not available until ODM was used for research. Because our data describing the efficacy of patching therapy are based on studies that likely result in similar levels of compliance, and these studies reveal that patching therapy is effective, it is not possible at this time to know if a higher daily dosage would produce better results. It is possible, as suggested by animal studies, that intervals with balanced input interleaved with periods of patching could be more effective than increased durations of patching (Mitchell et al., 2006) . ODM is the ideal tool to provide quantitative insight into the dose-response relationship of patching treatment, which is critical to tailor treatment regimens.
Terminology related to response
Visual acuity is the most common, well-used, primary outcome measure of amblyopia treatment. Stewart et al. suggested that visual outcome can be described in three ways: firstly, by calculating the change in the visual acuity of the amblyopic eye; secondly, by calculating the amount of residual amblyopia (acuity difference between the amblyopic and fellow eye at the outcome); thirdly, by calculating the proportion of the visual deficit corrected (proportional improvement), which also takes into account any visual development that might naturally occur in the fellow eye (Stewart, Moseley, & Fielder, 2003) . In addition, an analysis of the dose-response should consider the treatment response to three major variables: the type of amblyopia, the age of the subject, and initial visual acuity (Stewart et al., 2005) .
The dose-response relationship for patching
It is widely accepted that compliance with patching treatment is important for improvement in visual acuity (Fielder et al., 1995; Loudon, Polling, & Simonsz, 2003; Simonsz et al., 1999; Stewart et al., 2004 Stewart et al., , 2007b , contrast sensitivity (Moseley et al., 1997) and stereoacuity . Stewart et al. reported a positive and predominantly linear relationship between the cumulative dose and response over at least the first 400 h reported (Stewart et al., 2007a) . According to their model, in order to achieve a 2-line logMAR gain in visual acuity, a cumulative dose of 170 h for a 4-year-old child is required, while a 236-h dose is required for a 6-year-old child. They advised that 150-250 h of occlusion must be applied in order to achieve a favorable outcome.
Due to the limited critical period of visual cortex plasticity (Wiesel & Hubel, 1963) , if the child's vision does not improve during the first 7 years of life, it is much harder or even impossible to achieve optimal vision improvement later in life (Hertle et al., 2007; Scheiman et al., 2005 Scheiman et al., , 2008 . Therefore, age is often considered as an important factor. Loudon's model incorporated two important parameters to calculate the occlusion dose rate (number of occlusion hours per day): visual acuity and age : Dose rate ¼ À6:63 Â ðdecimal acuity of the amblyopic=fellow eyeÞ þ 0:5 Â age in years þ 4:97
This formula was used to estimate the dose rate in a couple of studies (Tjiam et al., , 2013 . However, it is not widely applied.
A recent study also confirmed a similar relationship in children with a wider age range (5-16 years old) (Fronius et al., 2014) . Despite comparable variability in patching dosages, vision improved throughout the age span; however, in order to achieve the same amount of improvement, patients younger than 7 years needed less dosage than older children. This finding suggests that treatment efficiency declined with age, which mirrors the results from studies that did not monitor dosage .
Peak response to patching
Besides the general linear trend of the dose-response relationship, a peak treatment response exists in an individual patient. In other words, there is a treatment period, usually at the beginning of the treatment, which is most efficient for gaining vision improvement. For example, within the first 6 weeks of patching, 80% of patients improved their vision (Agervi et al., 2010; Stewart et al., 2004) ; 4 h/day of an occlusion dose rate can achieve a plateau of improvement (Stewart et al., 2007a,b) ; Wallace et al. found that the median time to best visual acuity was 71 days . All of these findings suggest that improving compliance during the first 3-6 months of patching treatment is particularly important.
Patching treatment can reach a plateau
The response of patching treatment can reach a plateau before achieving equal visual acuity to the fellow eye. We refer to this gap as ''residual amblyopia''. Due to some neural substrate limitation, many amblyopes will have some residual amblyopia, regardless of their compliance. According to a PEDIG study, when the amblyopic eye stops improving vision with 2 h of daily patching, increasing the daily patching dosage to 6 h results in more improvement compared with continuing 2-h patching (Wallace, Lazar et al., 2013) . Although residual amblyopia is not usually considered to be fully treatable, one intensive ''final push'' option is to combine patching and atropine (Wallace et al., 2011) . Because compliance decreases with time, such a suggestion of using a stronger dosage may bring about an increased challenge in compliance, particularly for those who had been previously treated with patching or atropine for a certain period.
The Dose-response relationship for atropine treatment
The success of atropine penalization for amblyopia treatment has been well established (Pediatric-Eye-Disease-Investigator- Group, 2002 Group, , 2009 Repka et al., 2004; Scheiman et al., 2008) . For example, the effect of atropine on amblyopia at a 6-month follow-up demonstrated that it is similar to patching treatment (Pediatric-Eye-Disease-Investigator-Group, 2003) . Also, during a follow-up at the age of 10 years, atropine treatment effects achieved before 7 years of age were maintained (Repka et al., 2008) . Furthermore, evidence shows that weekday and weekend atropine treatment are equally effective in both mild and severe amblyopia (Repka et al., 2009) . Atropine was recommended as a first-line treatment, but it has not been widely applied in clinical settings (Jin et al., 2013; Stewart, Moseley, & Fielder, 2011) . One reason could be that there is no study to clarify the dose-response relationship in atropine treatment.
An investigation of compliance and further dose-response of atropine treatment could also be critical for the following three reasons: (1) As a pharmaceutical, atropine may have more serious side effects than the adhesive patch, as mentioned in Section 2.4. Thus, it is critically important to find the minimal atropine dose.
(2) Unlike patching, which can be immediately removed, atropine affects accommodation, pupil size, and near visual acuity for more than 72 h (Matta & Silbert, 2013) . As has been reported, atropine treatment has a risk of inducing reverse amblyopia (degraded vision in the treated eye) if not monitored closely (Hainline et al., 2009; Holmes et al., 2004) . Thus, the question of when to cease atropine treatment is pivotal. (3) Atropine may take a longer time to be effective. In a randomized clinical trial on patching and atropine, by 5 weeks, 56% of patients were successfully treated in the patching group and only 33% in the atropine group; by 6 months, these percentages were similar (79% and 74%, respectively) (Pediatric-Eye-Disease-Investigator-Group, 2002).
In summary, there are many unknowns regarding the dose-response relationship for atropine treatment. As a result, this treatment may require more frequent monitoring to prevent the development of deprivation amblyopia in the treated eye.
Causes of non-compliance with amblyopia therapy
To improve patients' compliance, it is important to understand why non-compliance occurs. There are many possible reasons for non-compliance in patching. For discussion, we can further classify these causes into non-psychosocial factors and psychosocial factors.
Non-psychosocial factors in patching treatment
Generally, non-psychosocial factors are often related to individual differences such as: the age at treatment, severity of amblyopia (or depth of amblyopia), the type of amblyopia, gender and the degree of binocularity. Here, regimen factors and demographic factors are also included.
Individual factors
Due to the limited window of visual cortex plasticity, amblyopia is considered to be more responsive to treatment among children younger than 7 years of age . However, there are limited samples for most studies and few investigative studies of compliance with treatment age. In children 3-8 years of age, there was no correlation between age and visual outcome (Awan, Proudlock, & Gottlob, 2005) . According to Loudon et al.'s study, the relationship between treatment age and compliance is borderline significant (p = 0.05); in their reference group, younger children (<4 years old) tended to have better compliance (63%) than older children (4-6 years old: 52%) and (>6 years old: 55%) . One conjecture for such a result could be that parents play a more important role in compliance for young children. However, one recent study reported that age has no significant impact on compliance .
It is controversial whether the severity of amblyopia is important for compliance. While some studies have suggested that the severity of amblyopia is the most significant factor (Arikan, Yaman, & Berk, 2005; Loudon et al., 2006) , one recent study reported that the severity of amblyopia has no significance with regard to compliance after fully controlling for covariates such as age, sex, race, cause of amblyopia and initial amblyopic eye visual acuity .
The type of amblyopia is not generally found to be associated with compliance Pediatric-Eye-DiseaseInvestigator-Group, 2003; Stewart et al., 2007b; Tjiam et al., 2013; Wallace, Stewart et al., 2013) . Similarly, gender and the degrees of binocular vision did not affect compliance.
Regimen factors
A higher dosage, which requires more daily effort, is often related to lower compliance. For instance, compliance with a 12-h patching regimen (50%) was significantly lower than to a 6-h regimen (66%) (Stewart et al., 2007b ). Children's activities on weekends may contribute to such non-compliance.
Demographic factors
Generally, important demographic predictors for low compliance included poor parental fluency in the national language, low socioeconomic status, country of origin and a low level of education . Because patients with non-native languages have lower compliance (Tjiam et al., 2011) , studies specifically targeting this population were designed (Tjiam et al., , 2013 .
Psychosocial factors
Psychosocial factors can be further divided into factors related to parents or caregivers (hereafter called ''parents'') and factors related to patients.
Commonly, psychosocial factors from families are estimated with questionnaires. For example, PEDIG used the Amblyopia Treatment Index (ATI) questionnaire to estimate the acceptability of amblyopia treatment and its impact on 3-to 7-year-old children and their families (Cole et al., 2001; Holmes et al., 2008) . The questionnaire includes 18 multiple-choice questions. These questions include three independent subscales: the adverse effects of treatment, treatment compliance, and social stigma. Answers to these questions demonstrate parents' feelings about their child's vision and difficulties in treating the child with patching. For children 7-13 years old, PEDIG designed the ATI for both parents and children separately (Felius et al., 2010) . Another group in the UK used a questionnaire based on Protection Motivation Theory and interviews to investigate psychological causes for low compliance, such as stress, stigma and motivation (Loudon et al., 2009; Searle et al., 2002) .
Psychosocial factors related to parents
The parent is a major factor of non-compliance in amblyopia treatment (Newsham, 2000) . Finding the real reasons for parents' contribution to non-compliance is critical. According to self-reported compliance with eye patching, only 54% of parents achieved clinicians' recommended patching durations (Searle et al., 2002) .
4.2.1.1. Lack of knowledge about amblyopia and treatment. It is commonly believed that parents receive inadequate training to effectively administer patching. Parents' lack of knowledge about their child's condition and treatment is significantly associated with non-compliance (Choong et al., 2004; Loudon et al., 2009) . Particularly, if the parent is a foreigner, poor knowledge due to a lack of communication might increase patient non-compliance.
In a randomized trial, a parent group receiving a written information leaflet had better knowledge of their child's condition and had better compliance (Newsham, 2002) , but the same methods were not significantly useful in another study (Tjiam et al., 2013) . As a matter of fact, compliance is much more complicated than training parents (Al-Yahya et al., 2012; Dixon-Woods, Awan, & Gottlob, 2006; Tjiam et al., 2013) .
4.2.1.2. Stress and a lack of motivation. In addition to ''lack of information'', it is often parental stress that accounts for poor compliance (Dixon-Woods, Awan, & Gottlob, 2006) . Distress related to difficulties in implementing treatment is significantly associated with non-compliance. Patching causes significant distress for the parents of 4-year-olds compared to the parents of older children (Loudon et al., 2009 ). Perceptions of vulnerability, stigma and logistic problems are also significantly associated with non-compliance (Choong et al., 2004; Loudon et al., 2009) .
A lack of motivation could be another factor of non-compliance for parents (Loudon et al., 2009) . A UK study (Loudon et al., 2009) found that perceived self-efficacy (parents' belief in the ability to perform recommended patching) and response efficacy (treatment beliefs) are positively associated with compliance. Appropriate health beliefs, such as the perceived seriousness of amblyopia and the efficacy of patching treatment both predict better compliance (Loudon et al., 2009 ). In other words, when the treatment makes sense to the parents, when the parents believe patching to be effective and when the parents understand that the benefits exceed the costs, we can predict better compliance with the patching regimen.
Further, perceived prohibition of the child's activities is a consistent barrier (Searle et al., 2002) . The child falling behind in school is another parental concern (Tjiam et al., 2010) . Fortunately, non-compliance is not associated with any particular personality style (Loudon et al., 2009) or religion (Tjiam et al., 2013) .
In addition to improving parents' knowledge through education, we should explore more approaches to enhance parents' compliance by lowering their stress, improving their belief in the efficacy of amblyopia treatment, and relieving their concerns about their children's activities or studies.
Psychosocial factors related to children being treated
There are a few major reasons for non-compliance from children. Carlton believes that children are able to describe their thoughts and opinions about amblyopia treatments in their daily lives. The author identified eleven themes for a pediatric selfreported amblyopia quality-of-life instrument. The themes include physical sensation of the treatment, pain, being able to play with other children, how other children have treated them, the ability to undertake schoolwork, the ability to undertake other tasks, and emotional feelings toward family members (Carlton, 2013) .
First, although children generally complain of the discomfort from eye patches, one obvious major reason of resistance from young children is due to short-term difficulties with vision from occluding the fellow eye (Tjiam et al., 2010) . Children undergoing patching treatment experience difficulty in undertaking their usual activities in school, social activities or hobbies.
Second, the patching experience has profound psychosocial impacts on the children. Children have to deal with the stigma, perceptions and responses of peers toward amblyopia treatment. Poor compliance with occlusion therapy seems correlated with indicators of social cohesion (Tjiam et al., 2011) . Furthermore, due to lower social acceptance, patching treatment affects self-esteem in these children (Horwood et al., 2005; Koklanis, Abel, & Aroni, 2006; Loudon et al., 2009; Webber et al., 2008; Williams et al., 2006) . The psychosocial distress associated with patching is associated with low compliance (Kim et al., 2013) .
Socio-economic factors
Hudak et al. also reported that poverty is associated with poorer results in amblyopia treatment; successful final visual acuity was 26.8% in the Medicaid group and 58% in the non-Medicaid group (Hudak & Magoon, 1997) . In a study using occlusion therapy to treat children after cataract extraction surgery, compliance is higher in children with private insurance (Drews-Botsch, Hartmann, & Celano, 2012) . All of these findings suggest that amblyopia compliance is also a socio-economic issue.
Health care provider and medical system
The patient-doctor relationship is a very important determinant of compliance (Loudon et al., 2009) . Although evidence has shown that written information is very important for compliance, 25% of clinicians never gave written information to parents (Newsham, 2010) . One of the key elements to success in achieving good compliance was the support provided to patients by the healthcare team. Regular, frequent phone contact with patients by healthcare team members promoted compliance (Tjiam et al., 2010) . Difficulty in scheduling appointments may also affect compliance because both parents and children have to take time off from work or school (Pediatric-Eye-Disease-Investigator-Group, 2011).
Eye patch materials
In addition to the non-psychosocial and psychosocial factors listed above, the physical properties of the patch itself (heat, irritation, poor adhesive material and design) are related to non-compliance. Of various eye patch brands, there are large differences in the comfort of wear and mechanical properties; eye patch permeability to moisture (''breathability'') is critical since children often wear the patch for a longer period of time (Al-Yahya et al., 2012) . Prescribing an appropriate brand of eye patch could contribute to increased satisfaction and consequently may improve compliance (Roefs et al., 2012) .
Non-compliance with atropine penalization
Unlike widely investigated non-compliance with patching, noncompliance with atropine was barely addressed in major atropine treatment articles. Theoretically, compared to patching, atropine requires less effort and is more easily applied: (a) The common psychosocial cause of non-compliance due to noticeable patches is less significant in atropine treatment. (b) Non-compliance with the daily dose of patching is minimized due to a simpler application of an eye drop. However, instillation of the atropine drops causes the uncomfortable effect of bright sunlight to the atropine-treated eye. Some children are resistant to eye-drops because of ocular sensitivity. Another potential cause of non-compliance is that atropine is still a new treatment, so some parents may not believe in the treatment and are worried about the toxicity of the drug. According to subjective compliance with atropine treatment shown in Table 3 , children 7-12 years old tend to have lower compliance than 3-to 7-year-old children. Further, many clinicians are also concerned about the side effects of atropine and the length of its effects (Newsham, 2010) .
Strategies to improve compliance
Concerning the non-compliance factors listed above, many practical strategies have been adopted in order to improve compliance.
Strategies relating to occlusion
Eye patches have been introduced with colorful and attractive patterns to be friendlier to children; patches have even been produced for boys and girls specifically. Material-wise, latex free eye patches are often used in US clinics.
To avoid uncomfortable feelings and the social stigma related to eye patches, researchers have invested major efforts in avoiding adhesives and changing the appearance to decrease poor cosmetic design from eye patches. For example:
(1) Min's glasses have a coating that blurs the viewer's side, but looks like normal glasses; this may improve compliance since the occlusion won't distract people or affect personal psychosocial factors (Min et al., 2000) . However, this product is not widely applied. (2) Without involving adhesives, transparent tape on glasses was reported to be helpful with compliance (Beneish et al., 2009) . (3) The Bangerter filter will not adhere to the eye and has been proven to degrade visual acuity in non-amblyopic eyes. Furthermore, visual acuity improvement following treatment with Bangerter filters is very similar to patching treatment, and there is a lower burden of treatment on the child and family. Bangerter filter treatment is a reasonable option to consider for the initial treatment of moderate amblyopia (Agervi et al., 2009; Rutstein et al., 2010 Rutstein et al., , 2011 . (4) Recently, liquid crystal glasses, a high-tech electronic device, have been developed to treat amblyopia. These liquid crystal lenses can be controlled with a programmed chip to provide intermittent occlusion. Such a novel intermittent occlusion technology may revolutionize traditional continuous patching occlusion. However, their effectiveness in treating amblyopia needs to be further confirmed. Although the liquid crystal glasses were reported favorably by young children, there is no report on their compliance (Spierer et al., 2010) . (5) Prosthetic contact lenses have been used to improve the cosmetics of occlusion (Collins et al., 2008) . However, because this special contact lens is too expensive to be affordable, it has not become popular.
Strategies targeting children
Presenting an educational cartoon story has proved to be effective in significantly improving the compliance in 4-to 5-year-old patients, at least within the first week after receiving the story (Tjiam et al., 2013) . This method can overcome language barriers and is particularly effective for foreign children speaking a second language. Occasionally, some clinics will explain patching to children before explaining it to parents (Newsham, 2010) .
Rewarding the child can also be beneficial. For example, reward stickers have been used to improve compliance ; other successful strategies include rewarding the child with small toys, asking the parent to invent a reward system at home, and letting the child pick the color of his or her eye patch (Tjiam et al., 2010) .
Strategies targeting parents
Providing written information and taking the time to explain amblyopia treatment to the parent is a simple, easy to implement yet effective method of improving compliance (Newsham, 2002) . To improve compliance, we can involve parents in the management decision of what daily dose to apply, so that it fits into the child's and the family's daily schedule with the least amount of disruption. Setting weekly goals for the amount of occlusion, but letting parents decide how to best achieve these goals might be an effective means of improving compliance (Tripathi et al., 2002) . Sharing strategies discussed by the parents of compliant patients may also help in enhancing parental self-efficacy (Loudon et al., 2009) .
In a recent ODM study, more frequent visits to the ophthalmologist are associated with higher compliance. Within 42 days after patching treatment, compliance was significantly higher for those patients who had frequent visits (Fig. 2) . The authors explained that individuals with frequent visits are more likely to comply because they understand the importance and benefit of patching .
Patching treatment may have a positive impact on family relationships. For example, some children may enjoy the patching experience in that they get rewards from their parent/guardian for complying with treatment; additionally, they may enjoy the extra time spent with their parent/guardian while they are supervised during the occlusion period (Pediatric-Eye-DiseaseInvestigator-Group, 2011). Sharing this kind of information may motivate parents to be more compliant.
To target the parents, besides the strategies listed above, compliance can be improved by providing memory aids and reminders, increasing supervision (Newsham, 2000) , and beginning with a less intensive patching regime (Newsham, 2010) . Pradeep et al. applied an educational/motivational intervention to higher-dose treated children (10 h per day and 6 days per week) and significantly improved compliance from 45.2% to 80.6% (Pradeep et al., 2014) . The intervention is the most comprehensive one to date, which involves strategies targeting education and motivation of both parents and children, while also including social supporting strategies.
Clinicians' strategies
Updating clinicians' knowledge of amblyopia treatment also plays an important role when the clinician communicates with patients and parents. Although there is a general move from fulltime to part-time patching since the PEDIG results were published, clinicians have not translated these evidence-based recommendations for amblyopia management widely into clinical practice in either North America (Jin et al., 2013) or the UK (Newsham, 2010) .
To clinicians, switching from patching to atropine is generally recognized as an efficient way to improve compliance and the treatment effect (Tjiam et al., 2010) . Combining both patching and atropine has been used on older children (7-12 years old) with residual amblyopia, but has not been very effective in moderate amblyopia (Scheiman et al., 2008) . However, there are few studies investigating the efficacy and compliance of the switch or a combination of treatments.
To avoid an interruption of children's activities, some clinicians have attempted to split patching hours. It was found that patients' visual acuity improvement achieved with splitting patching hours is similar to those with continuous patching hours. Subjective compliance in the splitting-hour patching group was 80% compared with 75% in the continuous patching group (Sachdeva et al., 2013) . Further objective compliance estimation is needed to better understand the effectiveness of such a strategy.
Applying devices or new technologies may improve investigations of compliance. From previous ODM studies, we notice that ODM itself did not improve compliance significantly, but it did bridge doctor-patient-parent communications. Januschowski et al. adopted an orthodontic device, the TheraMon Ò microsensor, to monitor patching compliance (Januschowski et al., 2013) . .
Although this microsensor is not widely used, its convenience and small size attest to the potential for monitoring objective compliance.
Social support strategies
Besides support from parents, greater support from other society members such as teachers, neighbors, friends and classmates, are associated with better compliance (Tjiam et al., 2011 ). The use of child-friendly novels-for example ''Jacob's Eye Patch'', an entertaining fiction book-may help in advocating the acceptance of eye patch wearing through the use of humor and encouragement which may improve overall social support (Shaw, Shaw, & Feiffer, 2013) . For the whole society, advocating social support and providing low-cost amblyopia therapy to families with financial barriers could also be beneficial to children with amblyopia.
Future directions
We have reviewed the compliance findings of the patching and atropine penalization amblyopia treatments conducted within the past 20 years. Five noteworthy points shed light on how to improve compliance with amblyopia treatments in the future:
(1) Compliance is generally low and decreases over time, in particular in patching treatment. This is a central issue to amblyopia treatments. Thus, our future tasks will be not only to increase average compliance, but also to change the current dynamic of compliance by slowing, maintaining or reversing the decreasing trend. (2) There is a pressing need to better understand compliance and the dose-response relationships to atropine penalization in the near future. (3) To improve compliance effectively, we have to consider the complexity of both non-psychosocial factors and psychosocial factors of both parents and children as the UK group (Pradeep et al., 2014) . After conquering the educational barriers for children and parents, more efforts should be invested in the psychosocial causes of non-compliance in the future. (4) New technology, such as ODM, which allows objective compliance to be quantified in real time, has significantly improved our understanding of compliance. New technology, such as liquid crystal occlusion glasses, may change continuous patching occlusion to intermittent occlusion, which has considerable potential to improve compliance. (5) New amblyopia treatments may bring new challenges to compliance. Recently, a new approach that uses video games has been suggested (Hess, Mansouri, & Thompson, 2010a , 2010b Hess et al., 2012; Li et al., 2012 Li et al., , 2014 . This new approach aims to provide binocular interaction training by adjusting the contrast of dichoptic images to balance the sensitivity differences between the amblyopic and fellow eyes. Because children are interested in the games, we expect fewer non-compliance issues with this new treatment. In practice, new binocular approaches probably need to be combined with traditional monocular approaches in order to be more effective. There are many unknowns about the optimal treatment strategy, which is inevitably dependent on high compliance.
In summary, although we have put forth a great deal of effort to understand and improve compliance with amblyopia treatment, we continue to search for new technology that allows objective compliance to be quantified in real time. Furthermore, we continue to seek more effective approaches to significantly improve compliance and treatment outcomes. Ultimately, our efforts will be rewarded by the benefit of the treatment to the child's vision.
